115 related articles for article (PubMed ID: 36942686)
1. Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer.
Zhang Y; Doran C; Le TK; Dreyfus B; Kola N; Sylvester BE; Lal L; Penrod JR; Meadows Shropshire S
Future Oncol; 2022 Dec; 18(40):4509-4523. PubMed ID: 36942686
[TBL] [Abstract][Full Text] [Related]
2. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Arbour KC; Mezquita L; Long N; Rizvi H; Auclin E; Ni A; Martínez-Bernal G; Ferrara R; Lai WV; Hendriks LEL; Sabari JK; Caramella C; Plodkowski AJ; Halpenny D; Chaft JE; Planchard D; Riely GJ; Besse B; Hellmann MD
J Clin Oncol; 2018 Oct; 36(28):2872-2878. PubMed ID: 30125216
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Drakaki A; Dhillon PK; Wakelee H; Chui SY; Shim J; Kent M; Degaonkar V; Hoang T; McNally V; Luhn P; Gutzmer R
Oncoimmunology; 2020 Oct; 9(1):1824645. PubMed ID: 33101774
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
Wang W; Gu X; Wang L; Pu X; Feng H; Xu C; Lou G; Shao L; Xu Y; Wang Q; Wang S; Gao W; Zhang Y; Song Z
Cancer Immunol Immunother; 2022 Jul; 71(7):1693-1703. PubMed ID: 34817639
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Xu Z; Li T; Hu X; Hao X; Xing P; Li J
Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
11. Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.
Julian C; Machado RJM; Girish S; Chanu P; Heinzmann D; Harbron C; Gershon A; Pfeiffer SM; Zou W; Quarmby V; Zhang Q; Chen Y
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1578. PubMed ID: 35075804
[TBL] [Abstract][Full Text] [Related]
12. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
La-Beck NM; Nguyen DT; Le AD; Alzghari SK; Trinh ST
Pharmacotherapy; 2020 Mar; 40(3):239-255. PubMed ID: 31930528
[TBL] [Abstract][Full Text] [Related]
15. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Griesinger F; Pérol M; Girard N; Durand-Zaleski I; Zacharias S; Bosquet L; Jänicke M; Quantin X; Groth A; Fleitz A; Calleja A; Patel S; Lacoin L; Daumont MJ; Penrod JR; Carroll R; Waldenberger D; Reynaud D; Thomas M; Chouaid C
Lung Cancer; 2022 Oct; 172():65-74. PubMed ID: 36007281
[TBL] [Abstract][Full Text] [Related]
16. Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
Hosokawa S; Ichihara E; Bessho A; Harada D; Inoue K; Shibayama T; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 Feb; 51(2):279-286. PubMed ID: 33049757
[TBL] [Abstract][Full Text] [Related]
17. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
18. Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.
Ma SC; Bai X; Guo XJ; Liu L; Xiao LS; Lin Y; Tan JL; Cai XT; Wen YX; Ma H; Fu QJ; Leng MX; Zhang YP; Long LL; Guo ZQ; Wu DH; Zhou JG; Dong ZY
BMC Med; 2022 Apr; 20(1):120. PubMed ID: 35410334
[TBL] [Abstract][Full Text] [Related]
19. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
20. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
